21 related articles for article (PubMed ID: 38489268)
1. Determinants of gastric cancer immune escape identified from non-coding immune-landscape quantitative trait loci.
Miliotis C; Ma Y; Katopodi XL; Karagkouni D; Kanata E; Mattioli K; Kalavros N; Pita-Juárez YH; Batalini F; Ramnarine VR; Nanda S; Slack FJ; Vlachos IS
Nat Commun; 2024 May; 15(1):4319. PubMed ID: 38773080
[TBL] [Abstract][Full Text] [Related]
2. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
3. Programmed Cell Death 1 Ligand 1 and Programmed Cell Death 1 Ligand 2 Are Expressed in Conjunctival Invasive Squamous Cell Carcinoma: Therapeutic Implications.
Wolkow N; Jakobiec FA; Afrogheh AH; Eagle RC; Pai SI; Faquin WC
Am J Ophthalmol; 2019 Apr; 200():226-241. PubMed ID: 30633894
[TBL] [Abstract][Full Text] [Related]
4. Interferon-γ-induced PD-L1 surface expression on human oral squamous carcinoma via PKD2 signal pathway.
Chen J; Feng Y; Lu L; Wang H; Dai L; Li Y; Zhang P
Immunobiology; 2012 Apr; 217(4):385-93. PubMed ID: 22204817
[TBL] [Abstract][Full Text] [Related]
5. PER2 binding to HSP90 enhances immune response against oral squamous cell carcinoma by inhibiting IKK/NF-κB pathway and PD-L1 expression.
Zhang Z; Sun D; Tang H; Ren J; Yin S; Yang K
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 37914384
[TBL] [Abstract][Full Text] [Related]
6. N
Liu Z; Wang T; She Y; Wu K; Gu S; Li L; Dong C; Chen C; Zhou Y
Mol Cancer; 2021 Aug; 20(1):105. PubMed ID: 34416901
[TBL] [Abstract][Full Text] [Related]
7. An update of knowledge on PD-L1 in head and neck cancers: Physiologic, prognostic and therapeutic perspectives.
Lenouvel D; González-Moles MÁ; Talbaoui A; Ramos-García P; González-Ruiz L; Ruiz-Ávila I; Gil-Montoya JA
Oral Dis; 2020 Apr; 26(3):511-526. PubMed ID: 30866171
[TBL] [Abstract][Full Text] [Related]
8. PD-L1 degradation pathway and immunotherapy for cancer.
Gou Q; Dong C; Xu H; Khan B; Jin J; Liu Q; Shi J; Hou Y
Cell Death Dis; 2020 Nov; 11(11):955. PubMed ID: 33159034
[TBL] [Abstract][Full Text] [Related]
9. DDX3 regulates cancer immune surveillance via 3' UTR-mediated cell-surface expression of PD-L1.
Chen HH; Yu HI; Chang JJ; Li CW; Yang MH; Hung MC; Tarn WY
Cell Rep; 2024 Mar; 43(3):113937. PubMed ID: 38489268
[TBL] [Abstract][Full Text] [Related]
10. Programmed Cell Death-Ligand-1 expression in Bladder Schistosomal Squamous Cell Carcinoma -
Madureira AC
Front Immunol; 2022; 13():955000. PubMed ID: 36148227
[No Abstract] [Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]